News
Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.
Zacks Investment Research on MSN2h
NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?
Novo Nordisk NVO announced that the FDA has granted accelerated approval to its blockbuster GLP-1 drug, Wegovy (semaglutide 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback